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NMR metabolomics reveals efects 
of Cryptosporidium infections on host cell 
metabolome
Christopher N. Miller1, Charalampos G. Panagos2,5, William R. T. Mosedale1, Martin Kváč3,4, Mark J. Howard2,6 
and Anastasios D. Tsaousis1* 
Abstract 
Background: Cryptosporidium is an important gut microbe whose contributions towards infant and immuno-
compromise patient mortality rates are steadily increasing. Over the last decade, we have seen the development of 
various tools and methods for studying Cryptosporidium infection and its interactions with their hosts. One area that is 
sorely overlooked is the efect infection has on host metabolic processes.
Results: Using a 1H nuclear magnetic resonance approach to metabolomics, we have explored the nature of the 
mouse gut metabolome as well as providing the irst insight into the metabolome of an infected cell line. Statisti-
cal analysis and predictive modelling demonstrated new understandings of the efects of a Cryptosporidium infec-
tion, while verifying the presence of known metabolic changes. Of note is the potential contribution of host derived 
taurine to the diarrhoeal aspects of the disease previously attributed to a solely parasite-based alteration of the gut 
environment, in addition to other metabolites involved with host cell catabolism.
Conclusion: This approach will spearhead our understanding of the Cryptosporidium-host metabolic exchange and 
provide novel targets for tackling this deadly parasite.
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Background
Cryptosporidiosis is a disease characterised by prolonged 
episodes of intense diarrhoea and is the second larg-
est cause of diarrheal disease and diarrhoea-associated 
deaths in infants across Africa and South Asia [1–4]. 
he aetiological agents of this disease are the apicompl-
exan parasites belonging to the Cryptosporidium genus. 
Cryptosporidiosis is also amongst one of the most com-
mon diseases of immunocompromised individuals, par-
ticularly HIV positive patients who are at 75–100% risk of 
contracting the disease during their lifetime [4, 5]. Nearly 
20 Cryptosporidium species and genotypes are respon-
sible for causing the disease in humans; although two 
species in particular, Cryptosporidium hominis and C. 
parvum, are most likely to be found in infected patients 
[2, 4, 6–9]. Infection occurs when an individual ingests 
the oocysts of the parasite, often by drinking a contami-
nated water source. Water treatment options are limited 
to iltering or boiling, which are generally not possible 
at an industrial scale and UV treatment, which is both 
expensive and rarely in place prior to outbreaks. Fail-
ing this, treatment is typically rehydration, although one 
drug has been shown to be efective, the broad spectrum 
anti-parasitic nitazoxanide [10]. he drug is far from 
ideal, however, and displays a range of undesirable side 
efects including cytotoxicity and nausea, as well as being 
limited to use in cases where the patients are immuno-
competent [11–14].
Until recently, a signiicant barrier to research into 
cryptosporidiosis has been the absence of a combined 
long-term in  vivo culturing system and comprehensive 
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model of host parasite interactions in addition to a heavy 
reliance on antibody based detection both in the scien-
tiic and the medical ield [1, 3, 15–19]. Recent papers 
have attempted to rectify this by proposing improved 
or entirely novel techniques for culturing the parasite 
ex vivo in cell cultures, using the cultured cancer cells as 
host cells [20, 21]. A recent study identiied that infec-
tion of COLO-680N cell cultures produced a longer 
term and higher production volume culture of the para-
site compared to previously existing in  vitro cultures 
[22, 23]. hese advances have allowed higher in depth 
microscopy-based studies and even promise to provide 
a solution to developing a genetic engineering platform 
for the parasite. However, beyond microscopy and locali-
sation studies [24], the knowledgebase of the host para-
site interaction remains largely undeveloped [3, 13, 14, 
21, 25]. One area lacking study is metabolomics. he 
study of parasite metabolomics is becoming increasingly 
important as the search for preventative treatments and 
cures becomes increasingly speciic [26]. However, before 
metabolomics can be used to satisfying efect, the tools 
must irst be properly established and demonstrated.
To our knowledge, only two peer-reviewed publications 
have explored the concept of the infection metabolome, 
one on mice and the other on human faecal samples [27, 
28]. he indings of each paper demonstrated a clear rela-
tionship between the infection and metabolic changes. 
Although working on diferent organisms and sampling 
sites, each study identiied the hexadecanoic acid as a 
signiicant component of these changes. Other changes 
noticed included a decrease in the relative abundance of 
amino acids in infected mice faeces, although an increase 
was previously in humans [27]. his was explained to be 
most likely due to the inherent variation between the 
diferent host species metabolomes, as highlighted by 
Saric et al. in 2008 [29]. However, this highlights a press-
ing need for further and wider reaching studies into 
the metabolome of Cryptosporidium infections. One 
approach would be to increase the variety of tools avail-
able, in addition to the gas chromatography–mass spec-
trometry (GC–MS) used in those papers [27–29].
Currently, many metabolomics studies utilise a GC–
MS approach, with great success, however 1H nuclear 
magnetic resonance (NMR) metabolomics can be used 
as an additional or alternative powerful tool for meta-
bolic screening. 1H NMR is a simple method that allows 
for a comparatively lossless analysis of metabolites, with 
fewer steps between sample recovery and analysis than 
GC–MS, ofering a huge advantage for studies involving 
time sensitive or limited resources restrictions, such ield 
research [29–33]. his translates to a more reliable result 
in terms of quantiication and immediate reproducibil-
ity. As such, NMR has already seen use in analysing the 
proile of Plasmodium falciparum, although the metabo-
lome of the apicomplexan parasite, as is the case with the 
rest of the group, remains largely unexplored compared 
to similar studies of other organisms [34].
Here we investigated the host-parasite interac-
tions, using a combination of microscopy and 1H NMR 
approaches. We validated our methodology by compar-
ing faecal proile results to the previously published stud-
ies, which used diferent methodologies, namely GC–MS 
[27, 28]. Further experimentation utilised a recently pub-
lished infectible culture, COLO-680N [22], to determine 
if any similarities or diferences in response to infection 
could be determined.
Results
Cell culture sample extractions
Extrapolated NMR data from COLO-680N (n = 38, C. 
parvum Iowa = 12, control = 12, C. hominis = 7, C. par-
vum Weru = 7) metabolite extractions, demonstrated 
clear diferences between the metabolomes of each 
individual strain/species of Cryptosporidium infection 
(Fig. 1a). Diferences could be observed between creatine, 
creatine phosphate, taurine and lactate spectra before the 
application of any analytical methods (Fig. 1b–d). Anal-
ysis using the Chenomx NMR Suite version 8.2 [35, 36] 
produced a list of 161 total compounds of varying con-
centrations across samples (Additional ile 1: Figure S1). 
he partial least squares discriminant analysis (PLS-DA) 
generated, produced ample separation of the Crypto-
sporidium-infected and uninfected cultures in multiple 
experiments (Fig.  2a, c). Furthermore, the separation of 
the individual infection groups suggests that diferences 
between both Cryptosporidium species and within indi-
vidual strains of C. parvum, may elicit diferent metabolic 
responses in cell cultures. It is important to note that all 
data points obtained from the 38 individual samples were 
input into the calculations, as any outliers should be visi-
ble via the resulting PLS-DA plots and pre-emptive prun-
ing of the data was deemed to be unreliable given the lack 
of pre-existing information on what should/shouldn’t be 
expected. he loading scores plot of the PLS-DA showed 
several compounds contributed heavily to the separa-
tions between groups, such as lactate, several fatty acid 
derivatives and taurine (Fig. 2b). 
All metabolites identiied in this manner were input 
into an online tool (MetaboAnalyst 3.0) producing a 
graph detailing which metabolic pathways were inlu-
enced by infection (Additional ile  2: Figure  S2) [37]. 
his approach identiied several pathways, including the 
biosynthesis of various amino acids, as well as ketones 
and CoA (Additional ile 2: Figure S2b–f). Within these 
pathways, metabolites were highlighted that were iden-
tiied via the PLS-DA as contributing reliably towards 
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diferences between groups. Full compound names are 
available in Additional ile 3: Figure S3.
Mice faecal sample extractions
Faecal samples from infected and uninfected mice were 
smeared onto microscope slides and stained with an 
aniline-carbol-methyl violet method [38], allowing the 
detection of C. parvum oocysts and thus validation of 
successful infections (Additional ile 4: Figure S4). Sam-
ples from both control and infected mice were taken at 
10  days post infection, while monitoring and counting 
the number of oocysts. he spectra produced by the 
NMR showed clear distinctions between the infected 
and uninfected mice, as well as distinctions between the 
diferent strains of infections (Fig.  3a). hough 18 indi-
vidual experiments were used to produce this data, the 
validity and reliability of each was conirmed by per-
forming a further nine technical replicate NMR scans. 
Several metabolites were readily distinguishable prior 
to the metabolomics analyses, including indicators of 
phosphorylation; taurine (Fig. 3b), creatine and creatine 
phosphate (Fig.  3c) and lactate (Fig.  3d). Processing the 
data from the mice guts (n = 18, six per infection) via the 
Chenomx NMR Suite version 8.2 platform produced a 
list of 151 compounds that were extrapolated from the 
spectra (Additional ile  5: Figure  S5). Statistical analysis 
of the data, with freely available Microsoft Excel Add-in 
“multi-base 2015”, by PLS-DA determined some sepa-
ration of the three conditions, (uninfected control, C. 
parvum Iowa II and C. parvum Weru infections), whilst 
maintaining group cohesion (Fig. 4a). he loading values 
of the variable compound contributions (Fig. 4b), suggest 
Fig. 1 Cell Culture infection NMR spectra. a Stacked NMR Spectra produced from the COLO-680N control cultures (green), either the C. parvum 
Iowa II (blue), C. parvum Weru (purple), or C. hominis groups, 7 days’ post infection. Direct comparisons of the spectra revealed several clearly 
identiiably diferences, including diferences in creatine and creatine phosphate (b), taurine (c) and lactate (d) levels. Noticeably, taurine levels were 
almost undetectable in C. hominis or C. parvum Weru infections. The spectra displayed are of individual experiments and are representative of the 
spectra observed throughout the groups
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certain metabolites were more signiicant to the separa-
tion of the groups than others. he presence of l-alanine 
and valine, two common amino acids, agrees with the 
previous literature and 2-oxoisocaproate is a component 
of the valine/leucine/isoleucine biosynthetic pathways 
reports [27, 28].
MetaboAnalyst 3.0 based analysis of the metabolites 
proposed that several amino acid biosynthesis path-
ways could be altered during an infection, such as the 
glycine, valine and taurine pathways. In addition, the 
mice infections displayed possible changes to other 
metabolic pathways (Additional ile  6: Figure  S6a) as 
those pathways furthest from the x, y axis intercept, 
representing both the overall completeness of the path-
ways and number of contributing detected metabolites 
respectively. As with Additional ile 2: Figure S2a–g, the 
pathways identiied in the manner, and the compounds 
discovered by the NMR demonstrated that infections 
caused changes in at least the valine (Additional ile 6: 
Figure S6c), glycine (Additional ile 6: Figure S6d) and 
taurine amino (Additional ile  6: Figure  S6e) acid bio-
synthetic pathways, in addition to several sugar path-
ways (Additional ile 6: Figure S6b, f, g). As before, full 
compound names are available in Additional ile  3: 
Figure S3.
Comparison of mice faecal and COLO‑680N metabolome 
changes
MetaboAnalyst data from Additional ile  2: Figure  S2 
and Additional ile  6: Figure S6, demonstrate that a 
number of altered pathways are shared between the 
mice (faecal) and cell culture metabolites, particu-
larly taurine and amino acid metabolic pathways. Gly-
cine synthesis was also shown to be afected to a large 
degree. Comparing the data from the mouse and cell 
culture responses directly revealed many metabolite 
levels responded similarly to infection regardless of 
host (Fig. 5).
Fig. 2 PLS-DA and loading plot of COLO-680N—infected cells NMR results. a PLS-DA statistical analysis of the information provided by the 
Chenomx screening produced clear groupings, separating the controls (green), C. parvum Iowa II infections (blue), C. parvum Weru infections 
(purple) and C. hominis infections (red), 7 days post infection. As the grouping areas do no overlap the separation between the infection conditions 
again indicates that metabolome diferences can be at least in part explained by diferent Cryptosporidium strains/species. b The loading biplot of 
the PLS-DA analysis shows lactate as a signiicant contributor to variation, in addition to taurine and myo-inositol among others. c PLS-DA statistical 
analysis of the information provided by the Chenomx screening using additional samples, also produced well-deined groupings, separating the 
controls (green), C. parvum Iowa II infections (blue), C. parvum Weru infections (purple) and C. hominis infections (red)
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Discussion
Previous studies recently demonstrated the successful 
long-term propagation of C. parvum in COLO-680N cell 
culture [22]. he ability of the cell culture to maintain the 
parasite for up to 8  weeks [22, 23] along with the pres-
ence of organelles around the parasite (e.g. feeder orga-
nelle) [21], implied a metabolic association between the 
parasite and the host. To investigate this, we have used 
1H NMR to explore the metabolomics of the infection.
Solution-state 1H NMR ofers a practical approach 
to metabolomics that is especially useful where sam-
ple volume sizes are particularly small [32, 33, 39]. 
Although GC–MS holds an advantage for detecting 
low-levels of metabolites with unique mass signatures, 
to determine the change in metabolite quantities, NMR 
provides a viable alternative [29–34]. Initial analysis of 
our data showed a clear distinction between the meta-
bolic ingerprints of infected and uninfected samples, 
even between infections of diferent strains of the par-
asite to some extent; with PLS-DA producing distinct 
groups of metabolite proiles, correlating to uninfected 
and infected samples (Fig.  2a, c). his may in-part be 
explained as the manifestation of the biochemical dif-
ferences between the species which contribute to their 
observed species speciicity.
Of importance is the degree to which these results, 
both from the in vitro and in vivo, agree with the previ-
ous literature. As a monolayered, simplistic culturing 
system, it should not be expected that the results would 
be a perfect mimicry of an in vivo experiment, although 
their similarity to other studies should indicate that the 
COLO-680N culture is a pragmatically suicient model 
for infection in more generalised studies such as this one. 
Our study also demonstrates that metabolic compounds 
l-alanine, isoleucine and succinic acid (succinate) were 
detected as contributors to the variance between the 
sample conditions that indicated infection. Moreover, 
even though valine was not detected in the uninfected 
controls, it was visible in the infected samples and in 
agreement with previous studies [27, 28].
Fig. 3 NMR Spectra of mice models of infection. a Stacked NMR Spectra produced from faecal samples of the control mice (green), or either the 
C. parvum Iowa II (blue) or C. parvum Weru (purple) groups, 10 days’ post infection. b Levels of taurine were substantially lower in the control or C. 
parvum Weru samples compared to C. parvum Iowa II. c Direct comparisons of the spectra revealed several clearly identiiably diferences, including 
diferences in creatine and creatine phosphate levels. d Lactate levels were also much higher in C. parvum Iowa II infected mice compared to the 
barely detectable levels in the control mice or C. parvum Weru infected groups
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he MetaboAnalyst data revealed several pathways 
were potentially inluenced by infection, including 
several that showed changes in both the mice and cell 
culture experiments, such as amino acid and CoA bio-
synthesis. Support for these indings is observed via 
the biosynthesis pathways for alanine and glycine that 
were highlighted previously in GC-MS studies as being 
potentially inluenced by infection [27, 28]. It is, how-
ever, important to note that these indings are based 
entirely on the presence/absence or relative changes 
in abundance of the noted metabolites and therefore 
cannot account for their speciic origin. For example, 
it is not possible to distinguish between an increase in 
metabolite level due to damage of a pathway, compared 
Fig. 4 PLS-DA and loading plot of mice model NMR results. a PLS-DA statistical analysis of the information provided by the Chenomx screening 
produced clear groupings, separating the controls (green), C. parvum Iowa II infections (blue) and C. parvum Weru infections (purple), 10 days post 
infection. As the grouping areas, indicated by the areas highlighted, do overlap, it can be said that the separation between the infection conditions 
represent some diferences in the metabolome, which correspond to the C. parvum strain. b The loading biplot of the PLS-DA analysis shows many 
of the compounds identiied by Chenomx contributed towards the separation and groupings. Those on the outer most edges, for example alanine, 
sarcosine, lactate and lactulose, had some of the greatest inluence on the amount of separation as determined by the PLS-DA
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to deliberate upregulation of a pathway, or even to the 
alterations of the gut microbiota. We hope to miti-
gate this by comparing the previous standards of these 
experiments, the mouse faecal samples, to the cell cul-
ture results.
As a parasite, Cryptosporidium is dependent on host 
derived biosynthetic pathways for survival. For example, 
C. parvum is incapable of producing most amino acids 
de-novo, instead relying heavily on the import of host 
metabolites via active channelling [40]. he biosynthetic 
pathway for glycine, threonine and serine was upregu-
lated, in both cell culture and animal experimentations, 
with particularly high levels of glycine detected. Both C. 
parvum and C. hominis are incapable of manufacturing 
these amino acids de novo, instead relying on scaveng-
ing host serine and glycine, utilising serine and glycine 
hydroxymethyltransferases to convert one to the other 
when needed [40, 41]. he reliance on host amino acids 
could provide a novel method for combating the infec-
tion, based upon previous studies that identiied other 
amino acid metabolic chains as potential targets [41, 42]. 
For example, glycine reuptake inhibitors (GRIs) that are 
often used in treating schizophrenia, could be utilised to 
partially starve the parasite of the metabolite.
In addition to the amino acid biosynthesis pathways, it 
is also apparent that taurine synthesis is also implicated 
in the metabolic proile of the disease as shown in the 
presented analyses; taurine has frequently been used in 
the past as an agent for inducing excystation for in vitro 
cultures as sodium taurocholate [43–46]. In the host, 
taurine has several roles, those relevant to the cell types 
involved include: cell membrane integrity, osmoregula-
tion and adipose tissue regulation. Perhaps most notably, 
however, is the role taurine plays as a pH regulator in the 
host mitochondria. he addition of taurine is another 
piece of evidence indicating host-mitochondria are 
somehow directly involved in the progress of infection. 
Previous metabolomic studies of faecal samples from 
Cryptosporidium-infected patients revealed increased 
taurine concentrations, which was explained away as 
characteristic of a decline in gut absorption as a result 
villi malformation [47, 48]. However, malabsorption 
is not an applicable explanation in the infected COLO-
680N cell cultures, wherein there is no external source of 
Fig. 5 Shared changes in metabolite levels between both cell cultures and mice. Those metabolites which showed a reliable contribution towards 
group separation (determined by positive PLS-DA values, displayed as green shaded cells in Additional ile 1: Figure S1 and Additional ile 5: S5) in 
both mice and cell culture experiments were recorded and their functions assigned. Those metabolites with direct or indirect involvement with 
mitochondria are labelled in red. The analysis was conducted for both the C. parvum Iowa II (a) and C. parvum Weru (b) infection experiments. 
*N-nitrosodimethylamine is a known carcinogen and not naturally produced by any known human or mammalian cell line or any member of the 
cryptosporidia and may represent either a product of the gut microbiota, contamination or un-characterised spectra peak
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the metabolite and thus is likely correlated to the infec-
tion metabolome. Increases were also observed in the 
abundance of adenosine derivatives (AMP, ADP and 
ATP); all showing an increased abundance in infected 
cells and mice in C. parvum Iowa II infections, along 
with a similar increase in creatine levels in C. parvum 
Weru infections. his further implicates the role of host 
mitochondria in the context of infection as each species 
and strain of parasite lacks creatine kinase, the only alter-
native source therefore being host creatine kinase which 
is often found in close association with mitochondria. 
Levels of pyruvate in C. hominis cell cultures and panto-
thenate in C. parvum Iowa II mouse infections suggest 
interactions with oxidative phosphorylation. his is of 
interest as the C. parvum genome contains a sequence 
for a potential pantothenate scavenging protein [49]. 
Moreover, the further increase in lactate levels detected 
in C. hominis cell cultures and C. parvum Iowa II mouse 
infected samples, compared to the controls, indicate a 
strong contribution from anaerobic pathways most likely 
from the host. his suggests that more ATP is being pro-
duced than the oxidative capacity of the host mitochon-
dria alone can maintain, producing a net increase in 
lactate as the oxygen debt increases. his suggests either 
an atypical drain of cellular ATP or a decrease in host cell 
aerobic capacity. Similar observations have been made 
in other intracellular parasites, including the microspo-
ridian Encephalitozoon cuniculi, in which the organism 
acquired specialised transporters to overcome its needs 
for ATP [50].
he indings above suggest that C. parvum and C. 
hominis infections are directly or indirectly inducing an 
increase in host mitochondrial activity. If factual, this 
would result in many oxygen free radicals being pro-
duced by the metabolic machinery. Consequently, cell(s) 
would respond with a matching increase in the synthesis 
of antioxidants such as taurine, which also sees increases 
during infection [51–53]. However, there also exists non-
related rationale for the detected increase in taurine, for 
example as a diuretic, which should not be a surprise in 
cryptosporidiosis, which is characterised by excessive 
water loss. his role sees taurine maintaining levels of 
the ionised forms of magnesium and potassium within 
the cell, producing a diuretic efect that may contribute 
towards the characteristic water-loss [48, 54–56]. Fur-
thermore, it has been found that taurine levels inluence 
production of short chained fatty acid, another aspect of 
host biology theorised to be scavenged by C. parvum and 
C. hominis [56–58]. Previous studies which have identi-
ied a rise in taurine levels in cryptosporidiosis patients’ 
stool, have dismissed the event as simply the result of 
the guts decrease in absorptive qualities. he presence 
of increased taurine in the in  vitro samples, which lack 
external sources that could be responsible for a build-up, 
would appear to dispute this conclusion. It is our inter-
pretation, therefore, that the intracellular role of taurine 
in this disease has been overlooked and that the patho-
physiology of this disease is more complicated than cur-
rently understood, extending beyond villi degradation.
Lastly, these results provide a potential for determining 
infections via a possible comparative 1H NMR of patient 
and reference biopsies. his would ofer an alternative 
approach in the medical ield, where current methods of 
diagnosis are reliant on multiple, separate, techniques to 
achieve the same result as NMR, with infections detected 
by laborious and often inaccurate microscopy in tandem 
with strain typing dependant on a successful PCR.
Conclusion
In conclusion, we have demonstrated for the irst time 
that the use of 1H NMR in the context of both medical 
and scientiic applications is indispensable in the ight 
against cryptosporidiosis. With the application of a more 
user-friendly and reproducible approach of metabo-
lomics, through the 1H NMR methodology described in 
this paper, it will now be easier for the Cryptosporidium 
community to further explore the remaining aspects of 
the disease metabolome in patients’ samples.
Methods
Cryptosporidium
hree isolates of Cryptosporidium were used in this 
study. he reference strain C. parvum Iowa II was 
obtained from Bunch Grass Farm in the United States, 
isolated from infected calves. he human isolate Crypto-
sporidium parvum Weru strain was originally isolated 
from an infected human patient and subsequently main-
tained by passing through SCID mice and supplied cour-
tesy of Prof. Martin Kváč of the Institute of Parasitology 
Biology Centre CAS, Czech Republic. he inal isolate 
used was the human isolate of C. hominis, supplied cour-
tesy of Prof. Rachel Chalmers from the Cryptosporidium 
Reference Unit, Singleton Hospital of NHS Wales.
Cell culture
75  cm2 monolayers of COLO-680N were infected and 
maintained as per the protocols outlined previously [22], 
using all three isolates of Cryptosporidium. In brief, for 
a typical infection, 4 × 106 oocysts were used to infect 
75  cm2 cell culture lasks at between 70 and 80% con-
luency (2 × 106 cells) giving a multiplicity of infection 
(MOI) of approximately 2. Infected cells were incubated 
for 7  days and monitored daily for their infectivity [22, 
23]. Prior to sample collection and metabolite extraction, 
the level of infection was monitored using Sporo-glo live 
staining under luoresce microscopy [22, 24]. A control 
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group was also established, following the same protocols 
as the infections, absent oocysts. Two separate experi-
ments were executed using a minimum of ive lasks per 
sample condition.
Animals and infection
Pregnant female BALB/c mice (Charles River, Germany) 
were housed in plastic cages with sterilized wood-chip 
bedding situated in IVC Air Handling Solutions (Tech-
niplast, Italy) with high-eiciency particulate air (HEPA) 
ilters and supplied with sterilized food and water ad libi-
tum. For this study, 7  day old BALB/c mice from the 
same mother, habiting the same cage were infected at 
the Institute of Parasitology, Biology Centre CAS using 
pre-established protocols detailed in Meloni and homp-
son, totalling ive mice per condition [59]. hree separate 
conditions, totalling six animals each, were used, infect-
ing with 100,000 oocysts of C. parvum Iowa II resus-
pended in 50 µl of PBS, 100,000 oocysts of the C. parvum 
Weru isolate resuspended in 50 μl of PBS or a PBS con-
trol (50  μl), given by oral gavage. he groups were kept 
physically separated and never allowed to interact. Infec-
tion was monitored and oocyst production was quanti-
ied from day-1 post-infection by aniline-carbol-methyl 
violet staining of faecal smears [60],  RIDA®QUICK 
Cryptosporidium, supplied by R-Biopharm. At 10-days 
post-infection, the mice were euthanized by cervical 
dislocation and decapitation. Samples of the ileum were 
dissected from the mice, measured to the same size to 
ensure reproducibility. Cryptosporidium hominis was not 
used in the mice infection experiments as it has previ-
ously shown that this species cannot infect these animals 
[61].
Sample preparation for NMR
he following protocol was adapted from published and 
well-established metabolic extraction methods used for 
NMR-based untargeted analysis of cell extracts [62–65]. 
Samples collected from the mouse experiments were 
retrieved from the contents of the ileum and surround-
ing intestinal structure. A section of ileum approximately 
5 mm in length was removed from the euthanised mouse 
by scalpel. A syringe containing 3  ml of 100% ethanol 
at room temperature was the inserted into the removed 
ileum and the ethanol pushed through the ileum over a 
petri dish. he sample was then collected via pipette and 
stored in three 1.5 ml tubes in 1 ml aliquots.
Collected samples were then centrifuged for 3  min 
at 10,000×g, the supernatant discarded, and the pel-
let weights recorded. he samples were then suspended 
by vortex in 2  ml of 75% ethanol, pre-heated to 80  °C, 
to immediately inhibit subsequent metabolic reactions, 
then transferred to a new tube and an additional ive ml 
of 75% ethanol added.
Two microlitre of 2  mm diameter glass beads were 
added to the samples and agitated by vortex for 30  s 
before incubating the samples for 3  min at 80  °C. he 
samples were vortexed for a further 30 s or until the sam-
ple was completely homogenised. Cell culture samples 
were collected by draining the media, adding 6 ml of eth-
anol at 80  °C to the culture lask and scraping the cells 
of the surface by cell scraper, transferring the mixture of 
lysed cells into 15 ml polyethylene tubes via a 10-ml sero-
logical pipette.
he samples were then transferred into 2  ml tubes, 
retaining the glass beads in 15  ml conical tubes. he 
beads were washed with an additional two ml of 80  °C, 
75% ethanol and again the liquid was transferred into 
sterile 2 ml tubes, retaining the glass beads in the tube.
Cell debris and general detritus were separated from 
the metabolite samples by centrifugation at 16,000×g 
for 10 min at room temperature and the resulting super-
natant transferred to new, sterile 2  ml microcentrifuge 
tubes and the remaining debris weighed for data nor-
malisation. he samples were then dried via Rotorvac 
for 12  h or until completely desiccated, at 40  °C, sus-
pended in 330 μl double distilled water and centrifuged 
at 2500×g for 10 min. he supernatants were recombined 
into ~ 1 ml aliquots per original sample in sterile 1.5 ml 
microcentrifuge tubes and frozen at − 20 °C until the day 
before NMR analysis. he sample tubes are subsequently 
placed into a freeze drier until completely desiccated, 
suspended in 1 ml of deuterium oxide (2H2O) and spiked 
with the sodium salt of the calibration and quantitation 
control compound: 3-(trimethylsilyl)-1-propanesulfonic 
acid (DSS), to a inal concentration of 20 μM and a tested 
pH of 7.5.
NMR protocol and analysis
Samples were analysed using a 4-channel Bruker Avance 
III 14.1 T NMR spectrometer (600  MHz 1H) equipped 
with a 5  mm QCI-F cryoprobe. For controls: six sepa-
rate, uninfected 25  cm2 COLO-680N 100% conluent 
monolayer cultures were analysed in addition to three 
uninfected BALB/c mice. Infected samples consisted 
of six 25  cm2 COLO-680N 100% conluent monolayers 
in addition to three c. parvum Iowa II infected BALB/c 
and three C. parvum Weru infected BALB/c mice. One-
dimension NMR datasets were acquired with a pulse 
repetition rate of 5  s over 128 scans, preceded by eight 
equilibrating dummy scans and suppression of the resid-
ual Deuterium Oxide solvent (HDO) resonance using 
presaturation. his was repeated 5 times per sample to 
ensure the reliability of the spectra produced. Processed 
NMR spectrographic datasets were produced by Topspin 
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3.2 and analysed using Chenomx NMR Suite version 8.2. 
Partial Least Squares Discriminant Analysis (PLS-DA) of 
the Chenomx data were generated with the freely availa-
ble Microsoft Excel Add-in “multi-base 2015” by Numer-
ical Dynamics, Japan (“Mutlibase for Microsoft Excel,” 
2015) and “Past3.x” by Øyvind Hammer, Natural History 
Museum, University of Oslo. Pathway predictions were 
produced by the MetaboAnalyst 3.0 web tool, using a 
hypergeometric test and relative-betweeness centrality 
(measure of centrality in a graph based on shortest paths) 
against Homo sapiens and Mus musculus databases for 
the tissue culture and mouse models respectively [37]. 
However, the analysis methods do contain limitations, 
relying largely on human interpretation of the initial 
results. As such it is not possible to determine whether 
a result is erroneous or simply unexpected and be able to 
prove the decision was free of bias, we elected to include 
all the indings from the analysis in this paper. In this 
case, the limitation is also a result of database compre-
hensiveness, whilst standards can be used in the lab to 
determine the accuracy of the dataset, it cannot detect 
compounds it has not been trained to recognise. Further-
more, as a result it is possible that such compounds may 
be misidentiied, cafeine for example is highly unlikely to 
be present in the sample but in the spirit of intellectual 
integrity the results have not be edited or altered in any 
way other than those required for easier reading. Fur-
thermore, compounds have been labelled based on their 
most likely source (human metabolome for COLO-680N 
samples, mouse metabolome for faecal (gut microbiome) 
samples or C. parvum if not found in either of the previ-
ous), whilst some (such as acetyl ornithine) may serve a 
purpose beyond “waste product” in other organisms, in 
this paper we do not consider potential outside sources 
[37]. On the other hand, as is the case with all new tech-
nologies and techniques, these limitations can only 
shrink with repeated use as more data becomes available 
to ill in the gaps.
Additional iles
Additional ile 1: Figure S1. COLO-680N Experiment Metabolites. All the 
metabolites identiied by 1H NMR analysis in infected and uninfected cells 
were explored via PLS-DA statistical analysis and the resulting values of 
each individual metabolite recorded. The colour coded heat map repre-
sents the signiicance to which each individual metabolite contributed to 
the identity of the sample groups. Red indicates that a metabolite showed 
large amounts of variance within identically treated samples, yellow indi-
cates that the amount of a metabolite varied little throughout all samples 
and green indicates that the metabolite was uniform within both control 
and infection groups but demonstrated a marked diference between 
them. Colour intensities were determined relatively from loading values, 
using the lowest negative value and highest positive value as the anchor 
points for red and green respectively, anchoring the mid-point yellow as 0.
Additional ile 2: Figure S2. Metabolic pathways detected in cell 
cultures’ NMR samples. a Data analysed by MetaboAnalyst 3.0, utilising 
all compounds which displayed some degree of change as a result of 
infection, produced a graph of pathways most heavily impacted (x axis) 
and pathways containing the most amount of the given compounds 
(pathway impact: y-axis), with statistical signiicance of the predicted 
pathways increasing as the colour ranges from yellow (low) to red (high). 
Six pathways were chosen to be of particular interest by their position on 
the graph, with metabolites present in the experimental samples high-
lighted in red, including: glycine, serine and threonine metabolism (b), 
taurine and hypotaurine metabolism (c), Alanine, aspartate and glutamate 
metabolism (d), synthesis and degradation of ketones (e), pantothenate 
and CoA biosynthesis (f) and arginine and proline metabolism (g).
Additional ile 3: Figure S3. Compound code key. KEGG ID to Com-
pound name conversion table for use with Additional ile 2: Figure S2 and 
Additional ile 5: Figure S5.
Additional ile 4: Figure S4. Staining of Cryptosporidium in faecal 
samples. Aniline-carbol-methyl violet stain of a faecal smear taken from a 
mouse in the infection group. The abundant presence of Cryptosporidium 
oocysts (arrows) indicates that the infection has been successful; and that 
the animal is producing oocysts. These samples were acquired at 7 days 
post-infection.
Additional ile 5: Figure S5. Mice Experiment Metabolites. All the 
metabolites identiied by 1H NMR analysis in infected and uninfected mice 
were explored via PLS-DA statistical analysis, the Principal Component 
values for each metabolite were then recorded. Metabolites that contrib-
uted towards variation within groupings are coded towards the red, whilst 
green represents metabolites that stayed relative unvaried within groups 
but demonstrated variation between groups and thus are of most interest. 
Yellow represents a general lack of variation between or within groups.
Additional ile 6: Figure S6. Metabolic pathways detected in mouse 
model NMR samples. a Data analysed by MetaboAnalyst 3.0, utilising 
all compounds which displayed some degree of change as a result of 
infection, produced a graph of pathways most heavily impacted (x axis) 
and pathways containing the most amount of the given compounds 
(pathway impact: y-axis), with statistical signiicance of the predicted 
pathways increasing as the colour ranges from yellow (low) to red (high). 
Six pathways were chosen to be of particular interest by their position 
on the graph, with metabolites present in the experimental samples 
highlighted in red, including: b pentose and glucuronate interconversions, 
valine, c valine, leucine and isoleucine biosynthesis, d glycine serine and 
threonine metabolism, e taurine and hypotaurine metabolism, f galactose 
metabolism and g starch and sucrose metabolism.
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